Skip to main content
main-content

16-06-2017 | Prostate cancer | Interview | Video

STAMPEDE trial changes standard of care

share
SHARE

Presenting author Nicholas James discusses the STAMPEDE trial results supporting the upfront use of abiraterone acetate in advanced prostate cancer patients beginning long-term androgen deprivation therapy.

2022 ASCO Annual Meeting coverage

Access the latest news and expert insight from the 2022 ASCO Annual Meeting

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.